Vinpocetine - instructions for use, dose, side effects, contraindications

one tablet contains 5 mg of vinpocetine as an active substance and auxiliary substances - sugar-refined sugar, sugar-milk (lactose), polyvinylpyrrolidone low molecular weight (povidone), potato starch, calcium stearate.

Description:

tablets white or white with a yellowish tinge of color, flat-cylindrical shape with a risk and chamfer.

Pharmacotherapeutic group: cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:Has vasodilator, antihypoxic, antiaggregatory action. Inhibits phosphodiesterase and increases the content of cyclic adenosine monophosphate in cells, which leads to a decrease in calcium content in the cytoplasm of smooth muscle cells and relaxation of myofibrils.It dilates the blood vessels of the brain, increases blood flow, mainly in ischemic areas, improves the supply of oxygen to the brain. Promotes the utilization of glucose and increases the level of catecholamines in the central nervous system, stimulates the metabolism of norepinephrine and serotonin in the brain tissues. Reduces platelet aggregation, blood viscosity, promotes increased erythrocyte deformability and normalization of venous outflow against a background of decreased resistance of cerebral vessels. Systemic blood pressure slightly decreases. In the elderly and senile age, the sensitivity of the cerebral vessels to the relaxing action of vinpocetin increases, which is due to the sensitization of the adenylate cyclase system - cyclic adenosine monophosphate upon aging.

Pharmacokinetics:

Quickly absorbed from the gastrointestinal tract, bioavailability of about 60%. The maximum concentration in the blood plasma is reached after 1 hour. Easily penetrates through gistogematicheskie barriers (including through the blood-brain barrier). Half-life is about 5 hours.

Indications:

- Insufficiency of cerebral circulation (including acute and recovery stage of ischemic stroke,restoration stage of hemorrhagic stroke, transient ischemic attack, encephalopathy, multi-infarct dementia).

- Vascular diseases of the retina and / or choroid of the eye (due to arteriosclerosis, angiospasm, thrombosis); degenerative changes in the macula caused by atherosclerosis or angiospasm; secondary glaucoma (due to vascular obturation).

- Age-related vascular or toxic (medicamentous) hearing disorders, Meniere's disease, dizziness of labyrinthine origin.

- Vegetative manifestations of climacteric syndrome.

Contraindications:Hypersensitivity, severe heart rhythm disturbances, coronary heart disease (severe course), acute stage of hemorrhagic stroke, pregnancy, lactation period, children under 18 years of age (insufficient data).

Dosing and Administration:

Inside for 1-2 tablets. 3 times a day for 2 months. Before cancellation of the drug should gradually reduce dosage. Possible repeated courses 2-3 times a year.

Side effects:

Reduction of arterial pressure, tachycardia, extrasystole, slowing of intraventricular conduction.

Overdose:

Symptoms: increased severity of side effects.

Treatment: gastric lavage, activated charcoal and symptomatic treatment.

Interaction:

Increases the risk of hemorrhagic complications against heparin therapy.

Special instructions:Care should be taken when carrying out work requiring rapidity of psychomotor reactions.

Form release / dosage:Tablets 5 mg.

Packaging:

For 10 tablets in a planar cell package. For 20 tablets in a polymer can. One bank or 2 contour mesh packages together with instructions for use in a pack of cardboard.

Storage conditions:

List B. In dry sheltered from light, but accessible to children, at a temperature of no higher than 25 ° C.

Shelf life:

2 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-002133/08

Date of registration:27.03.2008

The owner of the registration certificate:BIOSINTEZ, PAO BIOSINTEZ, PAO Russia

Manufacturer: & nbsp

BIOSINTEZ, PAO Russia

Representation: & nbspBIOSINTEZ JSC BIOSINTEZ JSC Russia

Information update date: & nbsp10.10.15

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)